You are here

Article info

Article menu

Download PDFPDF

XML
Rare disease
CASE REPORT
Limited auricular relapsing polychondritis in a child treated successfully with infliximab

Authors

  • Jubran Theeb Alqanatish Department of Paediatrics, King Abdulaziz Medical City and King Saud Bin Abdulaziz University for Health Sciences - Ministry of National Guard, Riyadh, Saudi Arabia PubMed articlesGoogle scholar articles
  • Basma Ali Alfarhan Department of Paediatrics, King Abdulaziz Medical City and King Saud Bin Abdulaziz University for Health Sciences - Ministry of National Guard, Riyadh, Saudi Arabia PubMed articlesGoogle scholar articles
  • Sara Mohammed Qubaiban Department of Paediatrics, King Abdulaziz Medical City and King Saud Bin Abdulaziz University for Health Sciences - Ministry of National Guard, Riyadh, Saudi Arabia PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Jubran Theeb Alqanatish, qanatishj{at}ngha.med.sa
View Full Text

Citation

Alqanatish JT, Alfarhan BA, Qubaiban SM
Limited auricular relapsing polychondritis in a child treated successfully with infliximab
BMJ Case Reports CP 2019;12:e227043.

Publication history

  • Accepted January 23, 2019
  • First published May 23, 2019.
Online issue publication 
September 27, 2019

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© BMJ Publishing Group Limited 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/